Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
OwnerDevalina Law, Rodger Henry +1inventors
InventorsDevalina Law, Rodger Henry, Xiaochun Lou
Life of this patent
Estimating the term…
Abstract
A novel crystalline cefdinir anhydrate and novel crystalline cefdinir hydrates, ways to make them and use them, compositions comprising them and made with them, and methods of treatment using them are disclosed.
Claims65
An isolated crystalline cefdinir lower hydrate or iso-structural hydrate thereof characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
An isolated crystalline cefdinir lower hydrate or iso-structural hydrate thereof having substantial crystalline purity, said isolated crystalline cefdinir lower hydrate and said iso-structural hydrate thereof characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
An isolated crystalline cefdinir lower hydrate or isolated iso-structural hydrate thereof having substantial crystalline purity and substantial chemical purity, said isolated crystalline cefdinir lower hydrate and said isolated iso-structural hydrate thereof characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
An isolated crystalline cefdinir lower hydrate or isolated iso-structural hydrate thereof having substantial crystalline purity, substantial chemical purity and substantial isomeric purity, said isolated crystalline cefdinir lower hydrate and said isolated iso-structural hydrate thereof characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A pharmaceutical composition comprising an isolated crystalline cefdinir lower hydrate or an isolated iso-structural hydrate thereof, said isolated crystalline cefdinir lower hydrate and said isolated iso-structural hydrate thereof characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of an isolated crystalline cefdinir lower hydrate or a isolated iso-structural hydrate thereof, said isolated crystalline cefdinir lower hydrate and said isolated iso-structural hydrate thereof characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
An isolated iso-structural hydrate of a crystalline cefdinir lower hydrate, said isolated iso-structural hydrate of said crystalline cefdinir lower hydrate characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
An isolated iso-structural hydrate of a crystalline cefdinir lower hydrate having substantial crystalline purity, said isolated isolated iso-structural hydrate characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
An isolated iso-structural hydrate of a crystalline cefdinir lower hydrate having substantial crystalline purity and substantial chemical purity, said isolated iso-structural hydrate characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
An isolated iso-structural hydrate of a crystalline cefdinir lower hydrate having substantial crystalline purity, substantial chemical purity and substantial isomeric purity, said isolated iso-structural hydrate characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
An excipient and an isolated iso-structural hydrate of crystalline cefdinir lower hydrate, said isolated iso-structural hydrate of said crystalline cefdinir lower hydrate characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of an isolated iso-structural hydrate of a crystalline cefdinir lower hydrate, said isolated iso-structural hydrate of said crystalline cefdinir lower hydrate characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.0.87H2O, said isolated crystalline cefdinir.0.87H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.0.87H2O having substantial crystalline purity, said isolated crystalline cefdinir.0.87H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.0.87H2O having substantial crystalline purity and substantial chemical purity, said isolated crystalline cefdinir.0.87H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.0.87H2O having substantial crystalline purity, substantial chemical purity and substantial isomeric purity, said isolated crystalline cefdinir.0.87H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A pharmaceutical composition comprising isolated crystalline cefdinir.0.87H2O, said isolated crystalline cefdinir.0.87H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of isolated crystalline cefdinir.0.87H2O, said isolated crystalline cefdinir.0.87H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.1.14H2O, said isolated crystalline cefdinir.1.14H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.1.14H2O having substantial crystalline purity, said isolated crystalline cefdinir.1.14H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.1.14H2O having substantial crystalline purity and substantial chemical purity, said isolated crystalline cefdinir.1.14H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.1.14H2O having substantial crystalline purity, substantial chemical purity and substantial isomeric purity, said isolated crystalline cefdinir.1.14H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A pharmaceutical composition comprising isolated crystalline cefdinir.1.14H2O, said isolated crystalline cefdinir.1.14H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of isolated cefdinir.1.14H2O, said isolated crystalline cefdinir.1.14H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.1.33H2O, said isolated crystalline cefdinir.1.33H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.1.33H2O having substantial crystalline purity, said isolated crystalline cefdinir.1.33H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.1.33H2O having substantial crystalline purity and substantial chemical purity, said isolated crystalline cefdinir.1.33H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.1.33H2O having substantial crystalline purity, substantial chemical purity and substantial isomeric purity, said isolated crystalline cefdinir.1.33H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A pharmaceutical composition comprising isolated crystalline cefdinir.1.33H2O, said isolated crystalline cefdinir.1.33H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of isolated crystalline cefdinir.1.33H2O, said isolated crystalline cefdinir.1.33H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.1.43H2O, said isolated crystalline cefdinir.1.43H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.1.43H2O having substantial crystalline purity, said isolated crystalline cefdinir.1.43H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.1.43H2O having substantial crystalline purity and substantial chemical purity, said isolated crystalline cefdinir.1.43H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
Isolated crystalline cefdinir.1.43H2O having substantial crystalline purity, substantial chemical purity and substantial isomeric purity, said isolated crystalline cefdinir.1.43H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A pharmaceutical composition comprising isolated crystalline cefdinir.1.43H2O, said isolated crystalline cefdinir.1.431H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of isolated cefdinir.1.43H2O, said isolated crystalline cefdinir.1.43H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A mixture comprising Cefdinir Crystalline Form A and an iso-structural hydrate of a crystalline cefdinir lower hydrate, said iso-structural hydrate of said crystalline cefdinir lower hydrate characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A pharmaceutical composition comprising Cefdinir Crystalline Form A and an iso-structural hydrate of a crystalline cefdinir lower hydrate, said iso-structural hydrate of said crystalline cefdinir lower hydrate characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of a mixture of Cefdinir Crystalline Form A and an iso-structural hydrate of a crystalline cefdinir lower hydrate, said iso-structural hydrate of said crystalline cefdinir lower hydrate characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A mixture comprising Cefdinir Crystalline Form A and crystalline cefdinir.0.87H2O, said cefdinir.0.87H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A pharmaceutical composition comprising Cefdinir Crystalline Form A and cefdinir.0.87H2O, said cefdinir.0.87H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7’, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of a mixture of Cefdinir Crystalline Form A and cefdinir.0.87H2O, said cefdinir.0.87H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A mixture comprising Cefdinir Crystalline Form A and crystalline cefdinir.1.14H2O, said cefdinir.1.14H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A pharmaceutical composition comprising Cefdinir Crystalline Form A and cefdinir.1.14H2O, said cefdinir.1.14H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of a mixture of Cefdinir Crystalline Form A and cefdinir.1.14H2O, said cefdinir.1.14H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A mixture comprising Cefdinir Crystalline Form A and crystalline cefdinir.1.33H2O, said cefdinir.1.333H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A pharmaceutical composition comprising Cefdinir Crystalline Form A and cefdinir.1.33H2O, said cefdinir.1.33H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of a mixture of Cefdinir Crystalline Form A and cefdinir.33H2O, said isolated cefdinir.33H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A mixture comprising Cefdinir Crystalline Form A and crystalline cefdinir.1.43H2O, said cefdinir.1.43H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A pharmaceutical composition comprising Cefdinir Crystalline Form A and cefdinir.1.43H2O, said cefdinir.1.43H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A method of treating bacterial infection in a human comprising administering thereto a therapeutically effective amount of a mixture of Cefdinir Crystalline Form A and cefdinir.1.43H2O, said cefdinir.1.43H2O characterized, in the monoclinic crystal system and C2 space group when measured with radiation at 0.7107 Å, by respective lattice parameters a, b and c of 23.95 ű0.03 Å, 4.984 ű0.006 Å and 15.87 ű0.01 Å and β of 108.88°±0.02° or, when measured with radiation at 1.54178 Å, comprising a powder diffraction pattern having 2θ values of about 5.9°, 8.1°, 11.8°, 15.7°, 16.2°, 22.6° and 23.1°, or by a combination thereof.
A process for converting crystalline cefdinir trihemihydrate, with or without surface water, to a crystalline cefdinir lower hydrate, or an iso-structural hydrate thereof, by heating at about 25° C. to about 70° C.
A crystalline cefdinir lower hydrate, or an iso-structural hydrate thereof, prepared by heating crystalline cefdinir trihemihydrate, with or without surface water, at about 25° C. to about 70° C.
A process for converting crystalline cefdinir trihemihydrate, with or without surface water, to a crystalline cefdinir lower hydrate, or an iso-structural hydrate thereof, by heating at about 25° C. to about 70° C. for about 30 minutes to about 24 hours.
A crystalline cefdinir lower hydrate, or an iso-structural hydrate thereof, prepared by heating crystalline cefdinir trihemihydrate at about 25° C. to about 70° C. for about 30 minutes to about 24 hours.
A process for converting a cefdinir lower hydrate, or an iso-structural hydrate thereof, to Cefdinir Crystalline Form A by providing a mixture comprising said cefdinir lower hydrate or said iso-structural hydrate thereof and an alcohol in which said cefdinir lower hydrate or said iso-structural hydrate thereof completely dissolves, causing Cefdinir Crystalline Form A to exist in said mixture, and isolating said Cefdinir Crystalline Form A.
Cefdinir Crystalline Form A prepared by a process comprising providing a mixture comprising a cefdinir lower hydrate or an iso-structural hydrate thereof and an alcohol in which said cefdinir lower hydrate or said iso-structural hydrate thereof completely dissolves, causing Cefdinir Crystalline Form A to exist in said mixture, and isolating said Cefdinir Crystalline Form A.
A process for converting cefdinir.0.87H2O, to Cefdinir Crystalline Form A by providing a mixture comprising cefdinir.0.87H2O and an alcohol in which said cefdinir.0.87H2O completely dissolves, causing Cefdinir Crystalline Form A to exist in said mixture, and isolating said Cefdinir Crystalline Form A.
Cefdinir Crystalline Form A prepared by a process comprising providing a mixture comprising cefdinir.0.87H2O and an alcohol in which said cefdinir.0.87H2O completely dissolves, causing Cefdinir Crystalline Form A to exist in said mixture, and isolating said Cefdinir Crystalline Form A.
A process for converting cefdinir.1.14H2O, to Cefdinir Crystalline Form A by providing a mixture comprising cefdinir.1.14H2O and an alcohol in which said cefdinir.1.14H2O completely dissolves, causing Cefdinir Crystalline Form A to exist in said mixture, and isolating said Cefdinir Crystalline Form A.
Cefdinir Crystalline Form A prepared by a process comprising providing a mixture comprising cefdinir.1.14H2O and an alcohol in which said cefdinir.1.14H2O completely dissolves, causing Cefdinir Crystalline Form A to exist in said mixture, and isolating said Cefdinir Crystalline Form A.
A process for converting cefdinir.1.33H2O, to Cefdinir Crystalline Form A by providing a mixture comprising cefdinir.1.33H2O and an alcohol in which said cefdinir.1.33H2O completely dissolves, causing Cefdinir Crystalline Form A to exist in said mixture, and isolating said Cefdinir Crystalline Form A.
Cefdinir Crystalline Form A prepared by a process comprising providing a mixture comprising cefdinir.1.33H2O and an alcohol in which said cefdinir.1.33H2O completely dissolves, causing Cefdinir Crystalline Form A to exist in said mixture, and isolating said Cefdinir Crystalline Form A.
A process for converting cefdinir.1.43H2O to Cefdinir Crystalline Form A by providing a mixture comprising cefdinir.1.14H2O and an alcohol in which said cefdinir.1.43H2O completely dissolves, causing Cefdinir Crystalline Form A to exist in said mixture, and isolating said Cefdinir Crystalline Form A.
Cefdinir Crystalline Form A prepared by a process comprising providing a mixture comprising cefdinir.1.43H2O and an alcohol in which said cefdinir.1.43H2O completely dissolves, causing Cefdinir Crystalline Form A to exist in said mixture, and isolating said Cefdinir Crystalline Form A.
Dependencies are inferred from the claim text.